Ocumension Therapeutics (HKG:1477)
5.33
-0.19 (-3.35%)
Sep 11, 2026, 4:08 PM HKT
Ocumension Therapeutics Revenue
Ocumension Therapeutics had revenue of 423.72M CNY in the half year ending June 30, 2026, with 152.78% growth. This brings the company's revenue in the last twelve months to 934.03M, up 71.79% year-over-year. In the year 2025, Ocumension Therapeutics had annual revenue of 804.35M with 92.75% growth.
Revenue (ttm)
934.03M CNY
Revenue Growth
+71.79%
P/S Ratio
4.17
Revenue / Employee
1.69M CNY
Employees
552
Market Cap
4.50B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 804.35M | 387.05M | 92.75% |
| Dec 31, 2024 | 417.31M | 170.94M | 69.38% |
| Dec 31, 2023 | 246.37M | 87.41M | 54.99% |
| Dec 31, 2022 | 158.96M | 102.81M | 183.11% |
| Dec 31, 2021 | 56.15M | 43.05M | 328.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.52B |
| Qyuns Therapeutics | 1.18B |
| Jacobio Pharmaceuticals Group | 852.85M |
| BioDlink International Company | 582.45M |
| Mirxes Holding Company | 166.32M |
| Abbisko Cayman | 112.29M |
| TransThera Sciences (Nanjing) | 40.93M |
| Shanghai Bao Pharmaceuticals | 19.67M |